Dr Luiza Steffens Reinhardt is an early career researcher who has developed a skillset in molecular biology, human genetics, and nanotechnology as means to tackle cancer therapy resistance.

Luiza recently completed dual doctorate degrees: a PhD degree in the field of molecules with biotechnological potential, focusing on novel therapies for Brain Cancer (the Federal University of Health Sciences of Porto Alegre, 2022) and a PhD degree in the field of Medical Genetics, focusing on molecular alterations in Breast Cancer that lead to treatment resistance and cancer progression (The University of Newcastle, 2023).

Luiza is an author on 39 publications (12 as first author), including publications in reputable journals such as Cell Death and Disease and BBA Reviews in Cancer and six book chapters (all as first author). Luiza has been cited 506 times, and has an H-index of 13. Despite her early career research stage, she has already obtained more than $320,000 in competitive grants, funding, and awards, and has nearly ten years of experience with wet-lab skills and a broad range of pre-clinical models.

Luiza has extensive expertise in cancer signalling, DNA damage response, and next-generation sequencing, which have led to the identification of novel markers of breast cancer recurrence and treatment resistance.

Luiza’s current research is particularly focused on targeting the p53 isoforms and using these variants as disease biomarkers.